勒布里奇祖马布降低了喘患者的2型炎症生物标志物水平:随机3期试验 (LAVOLTA I和II) 的数据
Stanley Szefler1, Jonathan Corren2, Jonathan I Silverberg3
1The Breathing Institute and Pediatric Pulmonary and Sleep Medicine Section, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO, USA.
Immunotherapy
|January 9, 2025
概括
在两项第三阶段试验中,勒布里奇祖马布显著降低了关键的喘生物标志物,包括免疫球蛋白E (IgE),围素和化学酶CCL13和CCL17. 这些减少在早期观察到,并在整个研究期间保持.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 喘是一种慢性呼吸道疾病,其特点是气道炎症.
- 干白素-13 (IL-13) 在喘病变发生过程中起着关键作用.
- 准IL-13信号传递是一种治疗策略,用于控制失控的喘.
研究的目的:
- 为了评估lebrikizumab,一种IL-13抑制剂,对非控制性喘患者的血清生物标志物的影响.
- 评估lebrikizumab在降低与喘相关的关键炎症标志物的疗效.
主要方法:
- 进行了两项复制,双盲,安慰剂控制的第三期临床试验 (LAVOLTA I和II).
- 患者接受lebrikizumab (37.5毫克和125毫克剂量每4周一次) 或安慰剂52周.
- 测量了血清生物标志物,包括免疫球蛋白E (IgE),质素,CC动机化学因配体 (CCL) 13和CCL17.
主要成果:
- 与安慰剂相比,Lebrikizumab治疗在第1周和第4周导致静素和CCL13的统计学上显著的早期下降.
- 在第一周服用125mg剂量时,观察到CCL17的显著减少.
- 在52周的治疗期间,这些生物标志物的减少一直持续.
- 在12周和24周观察到IgE显著下降.
结论:
- 勒布里奇祖马布有效地降低了非控制性喘患者的关键炎症生物标志物.
- 这项研究表明IL-13抑制对多种喘相关血清标志物的影响.
- 这些发现支持lebrikizumab作为喘向治疗的潜力.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231
01:17Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K